The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Capitol Hill

At Senate confirmation hearing for NIH directorship, Bertagnolli focuses on clinical trials, data analytics, health equity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

At a Senate hearing that considered her nomination to the post of NIH director, Monica Bertagnolli laid out an agenda that includes expanding access to clinical trials and making health care innovation affordable and accessible to the public.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase III open-label, multicenter, randomized DeLLphi-305 study.
Clinical Roundup

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors. 
Clinical Roundup

Perioperative Imfinzi + Padcev improves EFS, OS, in MIBC, phase III trial finds

Perioperative Imfinzi (durvalumab) plus neoadjuvant Padcev (enfortumab vedotin) reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer, according to the VOLGA phase III trial. The combination demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival and key secondary endpoint of overall survival in patients with muscle-invasive bladder cancer versus standard of care. 
Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account